Goryeb Children's Hospital

Morristown, New Jersey 07962

4 studies enrolling now · 17 studies all time

What they study most

Arthritis, Juvenile Idiopathic, Colitis, Ulcerative, Crohn's Disease, Crohn's Disease (CD), Functional Constipation in Children Ages 6-17 Years, Growth Hormone Deficiency in Children, Growth Hormone Disorder, Immune Thrombocytopenia, Irritable Bowel Syndrome With Constipation, Leukemia, Pediatric, Muscular Atrophy, Spinal, Pediatric Growth Hormone Deficiency

Studies at this site

• Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome — Recruiting now
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Recruiting now
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) — Recruiting now
• Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry — Recruiting now
• A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow — Running, not enrolling
• A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day — Running, not enrolling
• A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4) — Completed
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) — Completed
• Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency — Completed
• Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children — Completed
• Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia — Completed
• Start Time Optimization of Biologics in Polyarticular JIA — Completed
• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation — Stopped early
• An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA) — APPROVED_FOR_MARKETING
• ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP — Completed
• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) — Completed